Breast CancerSIDEMARANCT07865884
Tissue Validation of Mammographic Breast Arterial Calcification in Mastectomy Specimens
An observational study of Breast Cancer and Vascular Calcification, run by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital.
Trial summary
Breast arterial calcification (BAC) is a common incidental finding on screening mammograms and has been associated with cardiovascular disease in women. However, every study in this field has been imaging-based. Read more about this study
- Who is it for?
- Ages 40 years and older, women only
- Conditions the study is for
- Breast Cancer, Vascular Calcification, Coronary Artery Calcification
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Oct 2026to 30 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive women undergoing upfront mastectomy for breast cancer at a single tertiary training and research hospital in Istanbul, Turkey.
Who may be able to join
- Female
- Aged 40 years or older
- Scheduled for mastectomy for invasive breast carcinoma or ductal carcinoma in situ. All mastectomy types are eligible: simple, modified radical, skin-sparing, nipple-sparing and subcutaneous
- Full-field digital mammogram performed within 6 months before surgery and available for review
- Written informed consent
Who cannot join
- Neoadjuvant chemotherapy or neoadjuvant endocrine therapy
- Previous surgery or radiotherapy to the ipsilateral breast
- Previous radiotherapy to the thoracic region
- Breast implant
- Inflammatory breast carcinoma
- Male breast cancer
Show all 10Show fewer
- Chronic haemodialysis treatment
- Known hereditary disorder of vascular calcification
- Only analogue film mammography available
- Mammographic images not assessable
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Does Breast Artery Histopathology Reflect Systemic Atherosclerosis in Patients Undergoing Upfront Mastectomy? Relationship With Mammographic and Coronary Artery Calcification: A Prospective Preliminary Study
Breast arterial calcification (BAC) is a common incidental finding on screening mammograms and has been associated with cardiovascular disease in women. However, every study in this field has been imaging-based. The accuracy of mammography for detecting breast arterial calcification has only ever been measured against another radiologist reading the same mammogram, never against the tissue itself. As a result, it is not known how much calcification mammography misses, nor whether what it shows represents medial (Monckeberg-type) calcification or true atherosclerosis.
This prospective observational study compares mammographic BAC with the histopathology of breast arteries obtained from mastectomy specimens. Women aged 40 years and older undergoing upfront mastectomy, without neoadjuvant therapy, for invasive breast cancer or ductal carcinoma in situ will be enrolled consecutively. Additional tissue blocks will be taken from tumour-free areas of the specimen and examined with von Kossa and elastic van Gieson stains to determine whether arterial calcification is present and whether it lies in the media or the intima. These findings will be compared with the preoperative mammogram, which is read independently and blind to the pathology result.
Read more
As a secondary and exploratory objective, coronary artery calcification will be scored from staging computed tomography images already acquired for cancer staging.
No additional tests, imaging, radiation exposure or blood sampling will be performed for the purposes of this study, and the surgical procedure will not be altered in any way.
Read the detailed description
This is a single-centre, prospective, cross-sectional diagnostic accuracy study. There is no randomisation, no control group and no intervention.
Rationale Artificial-intelligence-based quantification of breast arterial calcification (BAC) in a cohort of 123,762 women has shown a dose-response relationship with major adverse cardiovascular events and incremental prognostic value over conventional risk scores. Systematic reviews support this association. Two questions remain unresolved. First, BAC is thought to be located in the tunica media rather than the tunica intima, making it medial arterial calcification rather than atherosclerosis, but direct histopathological verification in breast tissue is very limited. Second, and more critically, the field has no external reference standard: reported sensitivity values measure agreement with a human reader, not with tissue.
Specimen Handling The operation is not modified for the study. The specimen is oriented in theatre with two sutures (single suture superior, double suture lateral). In addition to diagnostic sampling, six research blocks are taken from macroscopically tumour-free areas: two from the upper outer quadrant, one from the upper inner quadrant, one from the lower quadrants, one from deep tissue adjacent to the prepectoral fascia and one from the central or retroareolar region. If there is any doubt about the adequacy of tissue for diagnosis, no additional block is taken; correct diagnosis always takes precedence.
Histopathological Assessment A stepwise staining algorithm is used: routine haematoxylin and eosin on all six blocks; von Kossa on blocks containing arteries of assessable calibre; elastic van Gieson on cases with calcification, to determine the layer involved. Presence, location (medial or intimal), circumferential extent and a 0-3 ordinal severity score are recorded, together with morphometric measurements made in free software. Intimal lesions are graded 0-4 using predefined morphological criteria, with grade 2 or above classified as atherosclerotic change. No additional immunohistochemistry is performed.
Mammographic Assessment The existing preoperative digital mammogram is read primarily in the mediolateral oblique projection. Presence of BAC, a 0-3 ordinal severity score and an estimated calcification area in square millimetres are recorded.
Coronary Artery Calcification Ordinal scoring is performed on staging positron emission tomography-computed tomography (PET-CT) or thoracic computed tomography (CT) images already acquired. The reader is a radiologist or nuclear medicine physician who is not among the mammography readers of this study. Cases without thoracic imaging, and those with previous coronary revascularisation, are excluded from this sub-analysis but remain in the primary analysis.
Blinding The pathologist is blind to mammographic and coronary findings. The mammography reader is blind to histopathology and coronary findings. The coronary calcification reader is blind to histopathology, mammography and the patient's clinical cardiovascular history. Twenty per cent of cases are re-read by independent second readers to measure inter-observer agreement.
Statistics With histopathology as the reference standard, sensitivity, specificity and predictive values of mammography are estimated with 95 per cent confidence intervals by the Wilson method. Because this is a preliminary study, the primary inference is drawn from the upper limit of the confidence interval rather than from the point estimate. Reporting follows the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guideline.
- Conditions
- Breast Cancer, Vascular Calcification, Coronary Artery Calcification, Atherosclerosis Cardiovascular Disease
- Keywords
- breast cancer, vascular calcification, breast arterial calcification, coronary artery calcification, atherosclerosis
- Medical subject headings
- Breast Neoplasms, Vascular Calcification, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Women undergoing upfront mastectomy | Women aged 40 years and older undergoing mastectomy without neoadjuvant therapy for invasive breast carcinoma or ductal carcinoma in situ, with a preoperative digital mammogram available for review. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity of mammography for histopathologically confirmed medial arterial calcification
Proportion of cases with histopathologically confirmed medial calcification of breast arteries in which breast arterial calcification is also reported on the preoperative mammogram. Histopathology serves as the reference standard. Reported with a 95 percent confidence interval calculated by the Wilson method. The primary inference is drawn from the upper limit of this interval.
Measured: From surgery to completion of histopathological assessment, up to 2 months per participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start15 Oct 2026 (estimated)
- Primary completion1 Nov 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Adnan Gundogdu, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07865884
- Sponsor's protocol ID
- SIDEMARA-2026
- Acronym
- SIDEMARA
- Status last verified
- Oct 2026
- First submitted
- 3 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Breast Artery Histopathology Reflect Systemic Atherosclerosis in Patients Undergoing Upfront Mastectomy? Relationship With Mammographic and Coronary Artery Calcification: A Prospective Preliminary Study
- ClinicalTrials.gov ID
- NCT07865884
- Acronym / sponsor ID
- SIDEMARA / SIDEMARA-2026
- Conditions
- Breast Cancer, Vascular Calcification, Coronary Artery Calcification, Atherosclerosis Cardiovascular Disease
- Keywords
- breast cancer, vascular calcification, breast arterial calcification, coronary artery calcification, atherosclerosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research HospitalUniversity, hospital or other
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 1 Nov 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast arterial calcification (BAC) is a common incidental finding on screening mammograms and has been associated with cardiovascular disease in women. However, every study in this field has been imaging-based. The accuracy of mammography for detecting breast arterial calcification has only ever been measured against another radiologist reading the same mammogram, never against the tissue itself. As a result, it is not known how much calcification mammography misses, nor whether what it shows represents medial (Monckeberg-type) calcification or true atherosclerosis.
This prospective observational study compares mammographic BAC with the histopathology of breast arteries obtained from mastectomy specimens. Women aged 40 years and older undergoing upfront mastectomy, without neoadjuvant therapy, for invasive breast cancer or ductal carcinoma in situ will be enrolled consecutively. Additional tissue blocks will be taken from tumour-free areas of the specimen and examined with von Kossa and elastic van Gieson stains to determine whether arterial calcification is present and whether it lies in the media or the intima. These findings will be compared with the preoperative mammogram, which is read independently and blind to the pathology result.
As a secondary and exploratory objective, coronary artery calcification will be scored from staging computed tomography images already acquired for cancer staging.
No additional tests, imaging, radiation exposure or blood sampling will be performed for the purposes of this study, and the surgical procedure will not be altered in any way.
Detailed description
This is a single-centre, prospective, cross-sectional diagnostic accuracy study. There is no randomisation, no control group and no intervention.
Rationale Artificial-intelligence-based quantification of breast arterial calcification (BAC) in a cohort of 123,762 women has shown a dose-response relationship with major adverse cardiovascular events and incremental prognostic value over conventional risk scores. Systematic reviews support this association. Two questions remain unresolved. First, BAC is thought to be located in the tunica media rather than the tunica intima, making it medial arterial calcification rather than atherosclerosis, but direct histopathological verification in breast tissue is very limited. Second, and more critically, the field has no external reference standard: reported sensitivity values measure agreement with a human reader, not with tissue.
Specimen Handling The operation is not modified for the study. The specimen is oriented in theatre with two sutures (single suture superior, double suture lateral). In addition to diagnostic sampling, six research blocks are taken from macroscopically tumour-free areas: two from the upper outer quadrant, one from the upper inner quadrant, one from the lower quadrants, one from deep tissue adjacent to the prepectoral fascia and one from the central or retroareolar region. If there is any doubt about the adequacy of tissue for diagnosis, no additional block is taken; correct diagnosis always takes precedence.
Histopathological Assessment A stepwise staining algorithm is used: routine haematoxylin and eosin on all six blocks; von Kossa on blocks containing arteries of assessable calibre; elastic van Gieson on cases with calcification, to determine the layer involved. Presence, location (medial or intimal), circumferential extent and a 0-3 ordinal severity score are recorded, together with morphometric measurements made in free software. Intimal lesions are graded 0-4 using predefined morphological criteria, with grade 2 or above classified as atherosclerotic change. No additional immunohistochemistry is performed.
Mammographic Assessment The existing preoperative digital mammogram is read primarily in the mediolateral oblique projection. Presence of BAC, a 0-3 ordinal severity score and an estimated calcification area in square millimetres are recorded.
Coronary Artery Calcification Ordinal scoring is performed on staging positron emission tomography-computed tomography (PET-CT) or thoracic computed tomography (CT) images already acquired. The reader is a radiologist or nuclear medicine physician who is not among the mammography readers of this study. Cases without thoracic imaging, and those with previous coronary revascularisation, are excluded from this sub-analysis but remain in the primary analysis.
Blinding The pathologist is blind to mammographic and coronary findings. The mammography reader is blind to histopathology and coronary findings. The coronary calcification reader is blind to histopathology, mammography and the patient's clinical cardiovascular history. Twenty per cent of cases are re-read by independent second readers to measure inter-observer agreement.
Statistics With histopathology as the reference standard, sensitivity, specificity and predictive values of mammography are estimated with 95 per cent confidence intervals by the Wilson method. Because this is a preliminary study, the primary inference is drawn from the upper limit of the confidence interval rather than from the point estimate. Reporting follows the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guideline.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Women undergoing upfront mastectomy | – | –Women aged 40 years and older undergoing mastectomy without neoadjuvant therapy for invasive breast carcinoma or ductal carcinoma in situ, with a preoperative digital mammogram available for review. |
Who may qualify
- Ages
- 40 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive women undergoing upfront mastectomy for breast cancer at a single tertiary training and research hospital in Istanbul, Turkey.
Key inclusion criteria (5 listed)
- Female
- Aged 40 years or older
- Scheduled for mastectomy for invasive breast carcinoma or ductal carcinoma in situ. All mastectomy types are eligible: simple, modified radical, skin-sparing, nipple-sparing and subcutaneous
- Full-field digital mammogram performed within 6 months before surgery and available for review
- Written informed consent
Key exclusion criteria (10 listed)
- Neoadjuvant chemotherapy or neoadjuvant endocrine therapy
- Previous surgery or radiotherapy to the ipsilateral breast
- Previous radiotherapy to the thoracic region
- Breast implant
- Inflammatory breast carcinoma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sensitivity of mammography for histopathologically confirmed medial arterial calcification
Time frame: From surgery to completion of histopathological assessment, up to 2 months per participant
Proportion of cases with histopathologically confirmed medial calcification of breast arteries in which breast arterial calcification is also reported on the preoperative mammogram. Histopathology serves as the reference standard. Reported with a 95 percent confidence interval calculated by the Wilson method. The primary inference is drawn from the upper limit of this interval.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
RecruitingPhase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Not yet recruiting
Podcast-Based Psychosocial Support for Women Newly Diagnosed With Breast Cancer
Breast Cancer
Recruiting
A Study of Skipping Radiation Therapy in People With Breast Cancer
HER2-positive Breast Cancer, Breast Cancer
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Vascular Calcification, run by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Adnan Gündoğdu, Medical Doctor (+90 5367173909, adnangundogdu89@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity of mammography for histopathologically confirmed medial arterial calcification (time frame: From surgery to completion of histopathological assessment, up to 2 months per participant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.